The invention provides a silica nanoparticle comprising a non-porous matrix of silicon-oxygen bonds, wherein the matrix comprises organic agents conjugated to...
The invention provides a silica nanoparticle comprising a non-porous matrix of silicon-oxygen bonds, wherein the matrix comprises organic agents conjugated to silicon or oxygen atoms in the matrix, the organic agents are conjugated to the matrix through linker L groups, wherein the linker L comprises, for example, an ester, urea, thiourea, or thio ether group, and wherein the diameter of the nanoparticle is about 15 nm to about 200 nm. The invention also provides novel methods of making and using the silica nanoparticles.
A system that incorporates teachings of the present disclosure may include, for example, an apparatus having an outer nozzle operable to discharge an outer stream...
A system that incorporates teachings of the present disclosure may include, for example, an apparatus having an outer nozzle operable to discharge an outer stream of a shell solution, and an inner nozzle operable to discharge an inner stream of a core solution intermixed with a plurality of materials. The outer stream can substantially surrounds the inner stream, thereby forming a combined stream. A plurality of capsules can be formed responsive to a force applied to the combined stream. At least a portion of the plurality of capsules are desirable capsules, each having a core encapsulated by a portion of the shell solution. The core can have at least one of the plurality of materials encapsulated by a portion of the core solution without protruding an outer surface of the portion of the shell solution.
An amphiphilic substance includes a hydrophobic group, and a polynucleotide group attached to the hydrophobic group. The polynucleotide group includes a first...
An amphiphilic substance includes a hydrophobic group, and a polynucleotide group attached to the hydrophobic group. The polynucleotide group includes a first polynucleotide segment and a second polynucleotide segment. The first and second polynucleotide segments are at least partially complementary and are bound together by interactions including base pairing. At least one of the first and second segments includes at least one of an aptamer and a nucleic acid-based enzyme. A lipid vesicle may include the amphiphilic substance, a first polar lipid that is an unstable vesicle former, and a polar liquid. Upon exposure to a rupture agent, the vesicle may rupture, releasing the contents of the vesicle. Substances that may be released from the vesicle include bioactive agents, such as drug agents.
This technology is a viral vector based on the murine leukemia virus (MLV), which has been favored for clinical gene therapy due to its preferential infectivity of...
This technology is a viral vector based on the murine leukemia virus (MLV), which has been favored for clinical gene therapy due to its preferential infectivity of human cell types. The original vector has been modified through the use of directed evolution targeting its protease (PR) gene, which has been found to produce increased stability for the viral vector. It is believed that this modification has the potential to be applied to all clinically-relevant viral vectors.
Applications
Clinical, such as delivery of gene therapy therapeutics
Biomedical Research by way of development of gene therapy therapeutics and general basic science research.
Benefits
Increased virus production.
Increased infection efficiency.
Increased safety (indirect benefit of decrease in required vector dose).
Tremendous potential exists for helical polypeptides that are water soluble (ionic) and remain stable at physiological conditions, variable environmental conditions including pH fluctuations, temperature changes, and in the presence of denaturing agents for gene delivery and cell-membrane penetration over commercially available products.
Libraries of helical polypeptides are screened for desired traits, i.e. efficient gene transfection compared to standard transfection reagents.
Dr. Pablo Perez-Pinera from the University of Illinois has developed a multiplexable and universal nuclease-assisted vector integration system for rapid generation of gene knock outs using selection that does not require customized targeting vectors, thereby minimizing the cost and time frame needed for gene editing. Importantly, this system is capable of remodeling native mammalian genomes through integration of DNA, up to 50 kb, enabling rapid generation and screening of multigene knockouts from a single transfection. Furthermore, this method facilitates activation of genes by introduction of specific promoters that allows for genomic scale activation screens.
Benefits
• Minimizes cost and time for gene editing • Multigene knockouts can be rapidly generated • Facile integration of large constructs up to 50 kb • Introduces speci c promoters for genomic scale activation screens
Profs. Hyungsoo Choi and Kevin Kim have developed a hydrogel nanoparticle carrier comprising gelatin covalently crosslinked with cyclodextrin, which has a longer drug...
Profs. Hyungsoo Choi and Kevin Kim have developed a hydrogel nanoparticle carrier comprising gelatin covalently crosslinked with cyclodextrin, which has a longer drug release profile than other carriers. The invented nano/micro carriers allows delivery of therapeutic and/or diagnostic agents that have low aqueous solubility. These hydrophobic molecules are confined inside hydrophobic pockets, and are released as polymer matrix degrades.
Application
This technology is used for delivering hydrophobic drugs in aqueous environments in the body.
Benefit
This invention boasts a longer release profile and allows drugs to be released over a longer period of time due to additional crosslinking between gelatin and cyclodextrin.
Dr. Kong from the University of IL has developed microparticles that create fibrin gels with desirable properties for wound healing products, drug delivery, and...
Dr. Kong from the University of IL has developed microparticles that create fibrin gels with desirable properties for wound healing products, drug delivery, and diagnostic tools. When blood clots it forms fibrin gel networks to close wounds temporarily for more permanent healing to take place. A significant problem with artificially-made fibrin gel networks is that they can be difficult to tune to attain desirable gelation rate and rigidity. The microparticles developed by Dr. Kong solve this problem by releasing thrombin in response to H2O2 to make gels with tunable, desirable properties.
Benefits
Encapsulating thrombin and MnO2 nanosheets allows for decoupling of gelation rate and gel rigidity.
Applications
This technology may be used for nano- or microparticles for drug delivery, biological gels for biomedical applications, or bleeding control/wound management.
